Zykadia (Ceritinib) Patent Expiration, LOE Window & CMS Spending

Zykadia (Ceritinib) by Novartis: FDA Orange Book core substance LOE 2032-01-18 (last listed 2037-12-13), 0 AB generics, $5.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN211225 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2032-01-18
Last Listed Patent or Exclusivity Date2037-12-13
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$5.0M
2024 Medicare Part D Spend$4.6M
2024 Medicaid Spend$492K
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 24.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.